OPRX Quote, Financials, Valuation and Earnings

Amedisys has a net margin of -10.03% compared to OptimizeRx's net margin of 10.26%. OptimizeRx's return on equity of -13.03% beat Amedisys's return on equity of 7.55%.

OptimizeRx has a consensus price target of $15.08, signalling upside risk potential of 29.47%. On the other hand Amedisys has an analysts' consensus of $96.86 which suggests that it could grow by 3.67%. Given that OptimizeRx has higher upside potential than Amedisys, analysts believe OptimizeRx is more attractive than Amedisys.

OptimizeRx has a beta of 1.283, which suggesting that the stock is 28.349% more volatile than S&P 500. In comparison Amedisys has a beta of 0.964, suggesting its less volatile than the S&P 500 by 3.612%.

OptimizeRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amedisys offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptimizeRx pays -- of its earnings as a dividend. Amedisys pays out -- of its earnings as a dividend.

OptimizeRx quarterly revenues are $21.9M, which are smaller than Amedisys quarterly revenues of $594.8M. OptimizeRx's net income of -$2.2M is lower than Amedisys's net income of $61M. Notably, OptimizeRx's price-to-earnings ratio is -- while Amedisys's PE ratio is 34.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx is 2.27x versus 1.31x for Amedisys. Usually stocks with elevated PS ratios are considered overvalued.

Health Catalyst has a net margin of -10.03% compared to OptimizeRx's net margin of -29.9%. OptimizeRx's return on equity of -13.03% beat Health Catalyst's return on equity of -20.06%.

OptimizeRx has a consensus price target of $15.08, signalling upside risk potential of 29.47%. On the other hand Health Catalyst has an analysts' consensus of $8.09 which suggests that it could grow by 121.67%. Given that Health Catalyst has higher upside potential than OptimizeRx, analysts believe Health Catalyst is more attractive than OptimizeRx.

OptimizeRx has a beta of 1.283, which suggesting that the stock is 28.349% more volatile than S&P 500. In comparison Health Catalyst has a beta of 1.559, suggesting its more volatile than the S&P 500 by 55.873%.

OptimizeRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Health Catalyst offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptimizeRx pays -- of its earnings as a dividend. Health Catalyst pays out -- of its earnings as a dividend.

OptimizeRx quarterly revenues are $21.9M, which are smaller than Health Catalyst quarterly revenues of $79.4M. OptimizeRx's net income of -$2.2M is higher than Health Catalyst's net income of -$23.7M. Notably, OptimizeRx's price-to-earnings ratio is -- while Health Catalyst's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx is 2.27x versus 0.73x for Health Catalyst. Usually stocks with elevated PS ratios are considered overvalued.

Humana has a net margin of -10.03% compared to OptimizeRx's net margin of 3.87%. OptimizeRx's return on equity of -13.03% beat Humana's return on equity of 10.08%.

OptimizeRx has a consensus price target of $15.08, signalling upside risk potential of 29.47%. On the other hand Humana has an analysts' consensus of $305.18 which suggests that it could grow by 35.68%. Given that Humana has higher upside potential than OptimizeRx, analysts believe Humana is more attractive than OptimizeRx.

OptimizeRx has a beta of 1.283, which suggesting that the stock is 28.349% more volatile than S&P 500. In comparison Humana has a beta of 0.494, suggesting its less volatile than the S&P 500 by 50.63%.

OptimizeRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humana offers a yield of 1.57% to investors and pays a quarterly dividend of $0.89 per share. OptimizeRx pays -- of its earnings as a dividend. Humana pays out 35.71% of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

OptimizeRx quarterly revenues are $21.9M, which are smaller than Humana quarterly revenues of $32.1B. OptimizeRx's net income of -$2.2M is lower than Humana's net income of $1.2B. Notably, OptimizeRx's price-to-earnings ratio is -- while Humana's PE ratio is 15.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx is 2.27x versus 0.23x for Humana. Usually stocks with elevated PS ratios are considered overvalued.

Option Care Health has a net margin of -10.03% compared to OptimizeRx's net margin of 3.51%. OptimizeRx's return on equity of -13.03% beat Option Care Health's return on equity of 15.22%.

OptimizeRx has a consensus price target of $15.08, signalling upside risk potential of 29.47%. On the other hand Option Care Health has an analysts' consensus of $38.56 which suggests that it could grow by 22.75%. Given that OptimizeRx has higher upside potential than Option Care Health, analysts believe OptimizeRx is more attractive than Option Care Health.

OptimizeRx has a beta of 1.283, which suggesting that the stock is 28.349% more volatile than S&P 500. In comparison Option Care Health has a beta of 0.763, suggesting its less volatile than the S&P 500 by 23.686%.

OptimizeRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptimizeRx pays -- of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend.

OptimizeRx quarterly revenues are $21.9M, which are smaller than Option Care Health quarterly revenues of $1.3B. OptimizeRx's net income of -$2.2M is lower than Option Care Health's net income of $46.7M. Notably, OptimizeRx's price-to-earnings ratio is -- while Option Care Health's PE ratio is 25.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx is 2.27x versus 1.03x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.